Oxford PharmaGenesis joined this year’s International Society for Medical Publication Professionals Annual Meeting (ISMPP, 11–13 April, 2016; National Harbor, MD, USA), which attracted over 500 publication professionals from the pharmaceutical industries, medical communication agencies, and publishers from around the globe. The attendees were Gordon Muir-Jones, Brian Falcone, Shilpa Aggarwal, Philip Joseph, and Scott Forbes from…

The International Committee of Medical Journal Editors (ICMJE) is consulting on a proposal that authors reporting clinical trials in member journals will be required to share the underlying de-identified individual-patient data with others (Taichman et al., 2016). We believe that this proposal pays insufficient attention to the unique needs of the patients who take part…

Privilege (/ˈprɪvəlɪdʒ/) ‘A special right, advantage or immunity granted or available only to a particular person or group.’ We all know what privilege is, but it can be difficult to appreciate fully how privilege – or the lack thereof – can affect us. It is especially difficult to understand the challenges faced by people with…

Oxford PharmaGenesis expertise in rare diseases was showcased in the April edition of PharmaTimes. The article ‘Time To Think Rare’ quoted Commercial Director Dr Richard White (http://tinyurl.com/hhk3xme) alongside other well-known figures in the rare diseases arena, including Alastair Kent (Director of the Genetic Alliance and Chair of Rare Disease UK) and Kay Parkinson (Chief Executive…

Oxford PharmaGenesis employees past and present were at the centre of the 2nd Annual HEOR Writing Workshop, held in Philadelphia on 17‑18 March 2016 and run by HealthEconomics.com and the Global Outcomes Group with sponsorship from the Mayes College of Healthcare Business and Policy. Attended by a mix of industry, agency and freelance medical writers,…

Dr Richard White, Commercial Director, and Dr Polly Field, Value Demonstration Leader, attended the Westminster Health Forum Keynote Seminar on Next steps for NICE, priorities for the pharmaceutical industry, and Accelerated Access Review. This was held on Thursday 14 January 2016 and Richard contributed the following article to the transcript of proceedings. The agenda for…